What is CRISPR Therapeutics's long-term debt?

CRISPR Therapeutics (CRSP) reported long-term debt of $585.47M in Q1 2026.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

CRISPR Therapeutics CRSP Long-Term Debt

Long-Term Debt at other companies

Beam TherapeuticsBEAM

$100.19M—

CelcuityCELC

$137.87M+30.9%

CG OncologyCGON

$3M—

BiogenBIIB

$6.29B+38.2%

Regeneron PharmaceuticalsREGN

$1.99B+0.1%

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's long-term debt?: CRISPR Therapeutics (CRSP) reported long-term debt of $585.47M in Q1 2026.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.